VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Measles Virus vaccine VEE/SIN-H Measles Virus vaccine VEE/SIN-H+F
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004187
  • Type: Recombinant vector vaccine
  • Status: Licensed
  • H hemagglutinin protein gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles (Pan et al., 2010).
  • Immunization Route: Intradermal injection (i.d.)
  • Vaccine Ontology ID: VO_0011422
  • Type: Recombinant vector vaccine
  • Status: Research
  • F fusion protein gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • H hemagglutinin protein gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Vector: chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles (Pan et al., 2010).
  • Immunization Route: Intradermal injection (i.d.)
Host Response Host Response

Monkey Response

  • Host Strain: Rhesus macaques
  • Vaccination Protocol: Juvenile rhesus macaques were vaccinated with a single intradermal (i.d.) injection of 108 VEE/SIN-H particles or 108 VEE/SIN-H particles plus 3 x 106 VEE/SIN-F particles (VEE/SIN-H+F). Two juvenile monkeys were vaccinated with one dose of 5,000 PFU of the Moraten strain of LAV intramuscularly (i.m.). Two juvenile monkeys were vaccinated with three doses of 0.5 ml of FIMV i.m. at 0, 4, and 8 weeks. Three infant rhesus macaques were immunized i.d. with 108 VEE/SIN-H particles plus 3 x 106 VEE/SIN-F particles and boosted 2 months later (Pan et al., 2010)
  • Challenge Protocol: For MV challenge, 104 tissue culture 50% infectious doses (TCID50) of the Bilthoven strain of MV were instilled intratracheally into anesthetized animals 12 to 17 months after vaccination. Monkeys were shaved and monitored frequently for development of a rash (Pan et al., 2010).
  • Efficacy: Neutralizing antibody remained above the protective level for more than 1 year after vaccination with VEE/SIN-H, VEE/SIN-H+F, or LAV. When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia, while FIMV-vaccinated monkeys were not (Pan et al., 2010).

Monkey Response

  • Host Strain: Rhesus macaques
  • Vaccination Protocol: Juvenile rhesus macaques were vaccinated with a single intradermal (i.d.) injection of 108 VEE/SIN-H particles or 108 VEE/SIN-H particles plus 3 x 106 VEE/SIN-F particles (VEE/SIN-H+F). Two juvenile monkeys were vaccinated with one dose of 5,000 PFU of the Moraten strain of LAV intramuscularly (i.m.). Two juvenile monkeys were vaccinated with three doses of 0.5 ml of FIMV i.m. at 0, 4, and 8 weeks. Three infant rhesus macaques were immunized i.d. with 108 VEE/SIN-H particles plus 3 x 106 VEE/SIN-F particles and boosted 2 months later (Pan et al., 2010).
  • Challenge Protocol: For MV challenge, 104 tissue culture 50% infectious doses (TCID50) of the Bilthoven strain of MV were instilled intratracheally into anesthetized animals 12 to 17 months after vaccination. Monkeys were shaved and monitored frequently for development of a rash (Pan et al., 2010).
  • Efficacy: Neutralizing antibody remained above the protective level for more than 1 year after vaccination with VEE/SIN-H, VEE/SIN-H+F, or LAV. When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia, while FIMV-vaccinated monkeys were not (Pan et al., 2010).
  • Host IFNG response
    • Description: VEE/SIN-H+F vaccinated rhesus macaques showed a significant increase in IFN-gamma producing cells in blood 1 to 2 weeks after vaccination as compared to the current live attenuated virus vaccine (LAV). The significant increase came after stimulation with the measles H-peptide (Pan et al., 2010).
    • Detailed Gene Information: Click Here.
References References
Pan et al., 2010: Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. Journal of virology. 2010; 84(8); 3798-3807. [PubMed: 20130066].
Pan et al., 2010: Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. Journal of virology. 2010; 84(8); 3798-3807. [PubMed: 20130066].